{
  "id": 20295385,
  "title": "Helus Pharma Touts Positive Data for Depression Drug",
  "url": "https://urgent.news/2026/11/16/helus-pharma-touts-positive-data-for-depression-drug",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T15:34:21.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/trading-ideas/movers/26/11/63298120/helus-pharma-touts-positive-data-for-depression-drug"
  },
  "original_language": "en",
  "account": null,
  "summary": "Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced symptoms in adults with major depressive disorder . Chief Executive Officer Michael Halstead said patients with persistent depression symptoms face a major unmet need for fast-acting, well-tolerated adjunctive therapies.…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}